Venom immunotherapy in patients with allergic reactions to insect stings

References

• Ring J, Behrendt H, de Weck A. History and classification of anaphylaxis. Chem Immunol Allergy. 2010;95:1–11.
   PubMedGoogle Scholar
• Golden DB. Anaphylaxis to insect stings. Immunol Allergy Clin North Am. 2015;35(2):287–302.
   PubMed Web of Science ®Google Scholar
• Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med. 1978;299:157–161.
   PubMed Web of Science ®Google Scholar
• Müller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in bee sting hypersensitivity. Bee venom versus whole-body extract. Allergy. 1979;34(6):369–378.
   PubMed Web of Science ®Google Scholar
• Brown SG, Wiese MD, Blackman KE, et al. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet. 2003;361(9362):1001–1006.
   PubMed Web of Science ®Google Scholar
• Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther. 2000;22(3):351–358.
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:CD008838.
   PubMedGoogle Scholar
• Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy. 2017;72(3):342–365.
   PubMed Web of Science ®Google Scholar
• Sturm GJ, Varga EM, Roberts G, et al. EAACI Guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2017. [Epub ahead of print].
   Google Scholar
• Epstein TG, Liss GM, Murphy-Berendts K, et al. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy. National surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–359.
   PubMed Web of Science ®Google Scholar
• Oude Elberink JO, van der Heide S, Guyatt GH, et al. Immunotherapy improves health-related quality of life of adult patients with dermal reactions following yellow jacket stings. Clin Exp Allergy. 2009;39:883–889.
   PubMed Web of Science ®Google Scholar
• Hockenhull J, Elremeli M, Cherry MG, et al. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technol Assess. 2012;16(12):1–110.
   PubMed Web of Science ®Google Scholar
• Ruëff F, Biló MB, Cichocka-Jarosz E, et al. Immunotherapy for hymenoptera venom allergy: too expensive for the European health care? Allergy. 2013;68(4):407–408.
   PubMed Web of Science ®Google Scholar
• Cavallucci E, Ramondo S, Renzetti A, et al. Maintenance venom immunotherapy administered at 3-month interval preserves safety and efficacy and improves adherence. J Investig Allergol Clin Immunol. 2010;20(1):63–68.
   PubMed Web of Science ®Google Scholar
• Golden DB, Kagey-Sobotka A, Valentine MD, et al. Dose dependence of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1981;67(5):370–374.
   PubMed Web of Science ®Google Scholar
• Konstantinou GN, Manoussakis E, Douladiris N, et al. A 5-year venom immunotherapy protocol with 50 μg maintenance dose: safety and efficacy in school children. Pediatr Allergy Immunol. 2011;22(4):393–397.
   PubMed Web of Science ®Google Scholar
• Brown SG, Wiese MD, van Eeden P, et al. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial. J Allergy Clin Immunol. 2012;130(1):162–168.
   PubMed Web of Science ®Google Scholar
• Ruëff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol. 2001;108:1027–1032.
   PubMed Web of Science ®Google Scholar
• Hemmer W, Focke M, Kolarich D, et al. Antibody binding to venom carbohydrates is a frequent cause for double positivity to honeybee and yellow jacket venom in patients with stinging-insect allergy. J Allergy Clin Immunol. 2001;108(6):1045–1052.
   PubMed Web of Science ®Google Scholar
• Hamilton RG, Wisenauer JA, Golden DB, et al. Selection of Hymenoptera venoms for immunotherapy on the basis of patient’s IgE cross-reactivity. J Allergy Clin Immunol. 1993;92(5):651–659.
   PubMed Web of Science ®Google Scholar
• Ebo DG, Van Vaerenbergh M, de Graaf DC, et al. In vitro diagnosis of Hymenoptera venom allergy and further development of component resolved diagnostics. Expert Rev Clin Immunol. 2014;10(3):375–384.
   PubMed Web of Science ®Google Scholar
• Tomsitz D, Brockow K. Component resolved diagnosis in Hymenoptera anaphylaxis. Curr Allergy Asthma Rep. 2017;17(6):38.
   PubMed Web of Science ®Google Scholar
• Köhler J, Blank S, Müller S, et al. Component resolution reveals additional major allergens in patients with honeybee venom allergy. J Allergy Clin Immunol. 2014;133(5):1383–1389.
   PubMed Web of Science ®Google Scholar
• Frick M, Muller S, Bantleon F, et al. rApi m 3 and rApi m 10 improve detection of honey bee sensitization in Hymenoptera venom-allergic patients with double sensitization to honey bee and yellow jacket venom. Allergy. 2015;70(12):1665–1668.
   PubMed Web of Science ®Google Scholar
• Blank S, Etzold S, Darsow U, et al. Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy. Hum Vaccin Immunother. 2017;13(10):2482–2489.
   PubMed Web of Science ®Google Scholar
• Eberlein B, Krischan L, Darsow U, et al. Double positivity to bee and wasp venom: improved diagnostic procedure by recombinant allergen based IgE testing and basophil activation test including data about cross-reactive carbohydate determinants. J Allergy Clin Immunol. 2012;130(1):155–161.
   PubMed Web of Science ®Google Scholar
• Severino MG, Campi P, Macchia D, et al. European Polistes venom allergy. Allergy. 2006;61(7):860–863.
   PubMed Web of Science ®Google Scholar
• Savi E, Incorvaia C, Boni E, et al. Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study. PLoS One. 2017;12(7):e0180270.
   PubMed Web of Science ®Google Scholar
• Korošec P, Šilar M, Eržen R, et al. Clinical routine use of basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on individuals with negative venom-specific IgE antibodies. Int Arch Allergy Immunol. 2013;161(4):363–368.
   PubMed Web of Science ®Google Scholar
• Lockey RF, Turkeltaub PC, Olive ES, et al. The Hymenoptera venom study. III: safety of venom immunotherapy. J Allergy Clin Immunol. 1990;86:775–780.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Müller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55:1005–1010.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Frati F, Dell’Albani I, et al. Safety of hymenoptera venom immunotherapy: a systematic review. Expert Opin Pharmacother. 2011;12(16):2527–2532.
   PubMed Web of Science ®Google Scholar
• Ruëff F, Przybilla B, Biló MB, et al.;European Academy of Allergy and Clinical Immunology Interest Group, Predictors of side effects during the build-up phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol. 2010; 126(1):105–111.
   PubMed Web of Science ®Google Scholar
• Diwakar L, Noorani S, Huissoon AP, et al. Practice of venom immunotherapy in the United Kingdom: a national audit and review of literature. Clin Exp Allergy. 2008;38(10):1651–1658.
   PubMed Web of Science ®Google Scholar
• Stoevesandt J, Hosp C, Kerstan A, et al. Risk stratification of systemic allergic reactions during Hymenoptera venom immunotherapy buildup phase. J Dtsch Dermatol Ges. 2014;12(3):244–256.
   PubMed Web of Science ®Google Scholar
• Brockow K, Kiehn M, Riethmuller C, et al. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997;100:458–463.
   PubMed Web of Science ®Google Scholar
• Gorska L, Chelminska M, Kuziemski K. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol. 2008;147(3):241–245.
   PubMed Web of Science ®Google Scholar
• Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol. 2009;19(3):225–229.
   PubMed Web of Science ®Google Scholar
• Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy. 2008;63(3):376–378.
   PubMed Web of Science ®Google Scholar
• Boni E, Incorvaia C, Mauro M. Dose-dependence of protection from systemic reactions to venom immunotherapy by omalizumab. Clin Mol Allergy. 2016;14:14.
   PubMedGoogle Scholar
• Stretz E, Oppel EM, Helen-Caroline R, et al. Overcoming severe adverse reactions to venom immunotherapy by using anti-IgE antibodies in combination with a high maintenance dose. Clin Exp Allergy. 2017;47(12):1631–1639.
   PubMedGoogle Scholar
• Tunon-de-Lara JM, Villanueva P, Marcos M, et al. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet. 1992;340(8824):908.
   PubMed Web of Science ®Google Scholar
• Stumpf JL, Shehab N, Patel AC. Safety of Angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacother. 2006 Apr;40(4):699–703.
   PubMed Web of Science ®Google Scholar
• White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol. 2008;101:426–430.
   PubMed Web of Science ®Google Scholar
• Stoevesandt J, Hain J, Stolze I, et al. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy. 2014;44(5):747–755.
   PubMed Web of Science ®Google Scholar
• Stoevesandt J, Hosp C, Kerstan A, et al. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol. 2015;114(5):411–416.
   PubMed Web of Science ®Google Scholar
• Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol. 2011;127(4):852–8544.
   PubMed Web of Science ®Google Scholar
• Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update 2016. Ann Allergy Asthma Immunol. 2017;118(1):28–54.
   PubMed Web of Science ®Google Scholar
• Zicha S, Tsuji Y, Shiroshita-Takeshita A, et al. Beta-blockers as anti-arrhythmic agents. Handb Exp Pharmacol. 2006;171:235–266.
   Google Scholar
• Coop CA, Schapira RS, Freeman TM. Are ACE-inhibitors and Beta-blockers dangerous in patients at risk for anaphylaxis? J Allergy Clin Immunol Pract 2017;5(5):1207–1211.
   PubMed Web of Science ®Google Scholar
• Müller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol. 2007;7(4):337–341.
   PubMed Web of Science ®Google Scholar
• Golden DB, Addison BI, Gadde J, et al. Prospective observations on stopping prolonged venom immunotherapy. J Allergy Clin Immunol. 1989;84:162–167.
   PubMed Web of Science ®Google Scholar
• Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol. 1991;87:702–709.
   PubMed Web of Science ®Google Scholar
• Lerch E, Müller U. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101:606–612.
   PubMed Web of Science ®Google Scholar
• Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97(2):579–587.
   PubMed Web of Science ®Google Scholar
• Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol. 1998;101(3):298–305.
   PubMed Web of Science ®Google Scholar
• Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol. 2000;105(2 Pt 1):385–390.
   PubMed Web of Science ®Google Scholar
• Hafner T, DuBuske L, Kosnik M. Long-term efficacy of venom immunotherapy. Ann Allergy Asthma Immunol. 2008;100(2):162–165.
   PubMed Web of Science ®Google Scholar
• Elberink JNGO, De Monchy JGR, Kors JW, et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol. 1997;99:153–154.
   PubMed Web of Science ®Google Scholar
• Light WC. Insect sting fatality 9 years after venom treatment (venom allergy, fatality). J Allergy Clin Immunol. 2001;107(5):925.
   PubMed Web of Science ®Google Scholar
• Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74(2):121–132.
   PubMed Web of Science ®Google Scholar
• Dodd NJ, Bond MG. Fatal anaphylaxis in systemic mastocytosis. J Clin Pathol. 1979;32(1):31–34.
   PubMed Web of Science ®Google Scholar
• Kors JW, van Doormaal JJ, de Monchy JG. Anaphylactoid shock following Hymenoptera sting as a presenting symptom of systemic mastocytosis. J Intern Med. 1993;233(3):255–258.
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Bonifacio M, Lombardo C, et al. Hymenoptera allergy and mast cell activation syndromes. Curr Allergy Asthma Rep. 2016;16(1):5.
   PubMed Web of Science ®Google Scholar
• Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am. 2000;14:641–657.
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostic, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–453.
   PubMed Web of Science ®Google Scholar
• Dubois AE. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol. 2004;4(4):291–295.
   PubMedGoogle Scholar
• Gonzales de Olano D, Alvarez-Twose I, Esteban-Lopez MI, et al. Safety and effectiveness of immunotherapy in patients with indolent sistemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol. 2008;121:519–526.
   PubMed Web of Science ®Google Scholar
• Bonadonna P, Zanotti R, Caruso B, et al. Allergen specific immunotherapy is safe and effective in patient with mastocytosis and hymenoptera allergy. J Allergy Clin Immunol. 2008;121:256–267.
   PubMed Web of Science ®Google Scholar
• Savi E, Peveri S, Makri E, et al. Comparing the ability of molecular diagnosis and CAP-inhibition in identifying the really causative venom in patients with positive tests to Vespula and Polistes species. Clin Mol Allergy. 2016;14:3.
   PubMedGoogle Scholar
• Frick M, Fischer J, Helbling A, et al. Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venomimmunotherapy. J Allergy Clin Immunol. 2016;138(6):1663–1671.
   PubMed Web of Science ®Google Scholar
• Ruiz B, Serrano P, Verdú M, et al. Sensitization to Api m 1, Api m 2, and Api m 4: association with safety of bee venom immunotherapy. Ann Allergy Asthma Immunol. 2015;114(4):350–352.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Mauro M, Ridolo E, et al. A pitfall to avoid when using an allergen microarray: the incidental detection of IgE to unexpected allergens. J Allergy Clin Immunol Pract. 2015;3(6):879–882.
   PubMed Web of Science ®Google Scholar
• Rodríguez Trabado A, Cámara Hijón C, Ramos Cantariño A, et al. Short-, intermediate-, and long-term changes in basophil reactivity induced by venom immunotherapy. Allergy Asthma Immunol Res. 2016;8(5):412–420.
   PubMed Web of Science ®Google Scholar